Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study

Cancer Epidemiology

Volumn 38, Issue 1, 2014, Pages 93-99

  Andersson, Therese M L ^a   Eriksson, Hanna ^b   Hansson, Johan ^b   Månsson Brahme, Eva ^b   Dickman, Paul W ^a   Eloranta, Sandra ^a   Lambe, Mats ^a,c   Lambert, Paul C ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cure; Flexible parametric model; Malignant melanoma; Population based; Relative survival; Survival

Indexed keywords

CURE; FLEXIBLE PARAMETRIC MODEL; MALIGNANT MELANOMA; POPULATION-BASED; RELATIVE SURVIVAL; SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894283716     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.12.006     Document Type: Article

References (43)

1. Diepgen T.L., Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002, 146(Suppl. 61):1-6.
2. Socialstyrelsen Cancer incidence in Sweden 2010. Official statistics of Sweden. Statistics - health and medical care 2011.
3. Jemal A., Devesa S.S., Hartge P., Tucker M.A. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001, 93(9):678-683.
4. Ferlay J.S.H., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocaniarcfr [accessed 17.01.13].
5. Masback A., Olsson H., Westerdahl J., Ingvar C., Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001, 11(5):435-445.
6. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
7. Xing Y., Chang G.J., Hu C.Y., Askew R.L., Ross M.I., Gershenwald J.E., et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010, 116(9):2234-2241. 10.1002/cncr.24966.
8. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206. 10.1200/JCO.2009.23.4799.
9. Metelitsa A.I., Dover D.C., Smylie M., de Gara C.J., Lauzon G.J. A population-based study of cutaneous melanoma in Alberta, Canada (1993-2002). J Am Acad Dermatol 2010, 62(2):227-232. 10.1016/j.jaad.2009.01.047.
10. Lindholm C., Andersson R., Dufmats M., Hansson J., Ingvar C., Moller T., et al. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer 2004, 101(9):2067-2078. 10.1002/cncr.20602.
11. Lachiewicz A.M., Berwick M., Wiggins C.L., Thomas N.E. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 2008, 144(4):515-521. 10.1001/archderm.144.4.515.
12. Joosse A., de Vries E., Eckel R., Nijsten T., Eggermont A.M., Holzel D., et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol 2011, 131(3):719-726. 10.1038/jid.2010.354.
13. Tryggvadottir L., Gislum M., Hakulinen T., Klint A., Engholm G., Storm H.H., et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010, 49(5):665-672. 10.3109/02841861003702528.
14. Lambert P.C., Thompson J.R., Weston C.L., Dickman P.W. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 2007, 8(3):576-594. 10.1093/biostatistics/kxl030.
15. Lambert P.C., Dickman P.W., Osterlund P., Andersson T., Sankila R., Glimelius B. Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. Int J Cancer 2007, 121(9):2052-2059. 10.1002/ijc.22948.
16. Andersson T.M., Lambert P.C., Derolf A.R., Kristinsson S.Y., Eloranta S., Landgren O., et al. Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. Br J Haematol 2010, 148(6):918-924. 10.1111/j.1365-2141.2009.08026.x.
17. Eloranta S., Lambert P.C., Cavalli-Bjorkman N., Andersson T.M., Glimelius B., Dickman P.W. Does socioeconomic status influence the prospect of cure from colon cancer - a population-based study in Sweden 1965-2000. Eur J Cancer 2010, 46(16):2965-2972. 10.1016/j.ejca.2010.05.028.
18. Huang L., Johnson K.A., Mariotto A.B., Dignam J.J., Feuer E.J. Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Res Treat 2010, 123(1):257-264. 10.1007/s10549-010-0752-z.
19. Francisci S., Capocaccia R., Grande E., Santaquilani M., Simonetti A., Allemani C., et al. The cure of cancer: a European perspective. Eur J Cancer 2009, 45(6):1067-1079. 10.1016/j.ejca.2008.11.034.
20. Cvancarova M., Aagnes B., Fossa S.D., Lambert P.C., Moller B., Bray F. Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 2013, 132(7):1700-1710. 10.1002/ijc.27802.
21. De Angelis R., Capocaccia R., Hakulinen T., Soderman B., Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999, 18(4):441-454.
22. Verdecchia A., De Angelis R., Capocaccia R., Sant M., Micheli A., Gatta G., et al. The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998, 77(3):322-329.
23. Yu B., Tiwari R.C., Cronin K.A., Feuer E.J. Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med 2004, 23(11):1733-1747. 10.1002/sim.1774.
24. Nationellt kvalitetsregister för hudmelanom. Diagnosår 1990-2008. Regionalt cancercentrum sydöst. Available from: [accessed 28.01.13]. http://www.vinkcancer.se/Global/Diagnoser/hudmelanom/rapporter/Melanom_NatKvalReg1990-2008.pdf.
25. Dickman P.W., Adami H.O. Interpreting trends in cancer patient survival. J Intern Med 2006, 260(2):103-117. 10.1111/j.1365-2796.2006.01677.x.
26. Perme M.P., Stare J., Esteve J. On estimation in relative survival. Biometrics 2012, 68(1):113-120. 10.1111/j.1541-0420.2011.01640.x.
27. Talback M., Dickman P.W. Estimating expected survival probabilities for relative survival analysis - exploring the impact of including cancer patient mortality in the calculations. Eur J Cancer 2011, 47(17):2626-2632. 10.1016/j.ejca.2011.08.010.
28. Hinchliffe S.R., Dickman P.W., Lambert P.C. Adjusting for the proportion of cancer deaths in the general population when using relative survival: a sensitivity analysis. Cancer Epidemiol 2012, 36(2):148-152. 10.1016/j.canep.2011.09.007.
29. Royston P., Parmar M.K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002, 21(15):2175-2197. 10.1002/sim.1203.
30. Andersson T.M., Dickman P.W., Eloranta S., Lambert P.C. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol 2011, 11:96. 10.1186/1471-2288-11-96.
31. Lambert P.C., Royston P. Further development of flexible parametric models for survival analysis. Stata J 2009, 9(2):265-290.
32. Nelson C.P., Lambert P.C., Squire I.B., Jones D.R. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 2007, 26(30):5486-5498. 10.1002/sim.3064.
33. Royston P. Flexible parametric alternatives to the Cox model, and more. Stata J 2001, 1(1):1-28.
34. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. 10.1056/NEJMoa1003466.
35. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9):809-819. 10.1056/NEJMoa1002011.
36. Romano E., Schwartz G.K., Chapman P.B., Wolchock J.D., Carvajal R.D. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011, 12(9):913-922. 10.1016/S1470-2045(10)70274-6.
37. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516. 10.1056/NEJMoa1103782.
38. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8):707-714. 10.1056/NEJMoa1112302.
39. Davies A., Briggs A., Schneider J., Levy A., Ebeid O., Wagner S., et al. The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med 2012, 3(1):e25-e36.
40. McKinnon J.G., Yu X.Q., McCarthy W.H., Thompson J.F. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003, 98(6):1223-1231. 10.1002/cncr.11624.
41. Pollack L.A., Li J., Berkowitz Z., Weir H.K., Wu X.C., Ajani U.A., et al. Melanoma survival in the United States, 1992-2005. J Am Acad Dermatol 2011, 65(5 (Suppl. 1)):S78-S86. 10.1016/j.jaad.2011.05.030.
42. Green A.C., Baade P., Coory M., Aitken J.F., Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012, 30(13):1462-1467. 10.1200/JCO.2011.38.8561.
43. Joosse A., Collette S., Suciu S., Nijsten T., Lejeune F., Kleeberg U.R., et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European organisation for research and treatment of cancer phase III trials. J Clin Oncol 2012, 10.1200/JCO.2011.38.0584.